These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 15452834

  • 1. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
    Argiris A, Li Y, Forastiere A.
    Cancer; 2004 Nov 15; 101(10):2222-9. PubMed ID: 15452834
    [Abstract] [Full Text] [Related]

  • 2. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
    Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA.
    J Clin Oncol; 2004 Jan 15; 22(2):262-8. PubMed ID: 14722034
    [Abstract] [Full Text] [Related]

  • 3. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
    Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA, Eastern Cooperative Oncology Group.
    J Clin Oncol; 2005 May 20; 23(15):3562-7. PubMed ID: 15908667
    [Abstract] [Full Text] [Related]

  • 4. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.
    Int J Radiat Oncol Biol Phys; 2004 Oct 01; 60(2):427-36. PubMed ID: 15380576
    [Abstract] [Full Text] [Related]

  • 5. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J.
    Cancer; 1999 Dec 01; 86(11):2364-9. PubMed ID: 10590379
    [Abstract] [Full Text] [Related]

  • 6. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
    Recondo G, Armand JP, Tellez-Bernal E, Domenge C, Belehradek M, De Vathaire F, Wibault P, Richard JM, Cvitkovic E.
    Laryngoscope; 1991 May 01; 101(5):494-501. PubMed ID: 1709437
    [Abstract] [Full Text] [Related]

  • 7. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH, Southwest Oncology Group, Head and Neck Working Group.
    Cancer; 2006 Jul 15; 107(2):319-27. PubMed ID: 16779801
    [Abstract] [Full Text] [Related]

  • 8. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
    Dunphy FR, Dunleavy TL, Harrison BR, Trinkaus KM, Kim HJ, Stack BC, Needles B, Boyd JH.
    Cancer; 2001 Mar 01; 91(5):940-8. PubMed ID: 11251945
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH, Mailliard JA, Suman VJ, Edmonson JH, Creagan ET, Nair S, Levitt R, Kugler JW.
    Cancer; 2002 Apr 15; 94(8):2224-31. PubMed ID: 12001121
    [Abstract] [Full Text] [Related]

  • 10. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H.
    J Clin Oncol; 2005 Dec 01; 23(34):8636-45. PubMed ID: 16275937
    [Abstract] [Full Text] [Related]

  • 11. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
    Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1087-95. PubMed ID: 15752888
    [Abstract] [Full Text] [Related]

  • 12. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A.
    Jpn J Clin Oncol; 2009 Apr 15; 39(4):225-30. PubMed ID: 19211574
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
    Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K.
    J Clin Oncol; 2007 Oct 20; 25(30):4800-5. PubMed ID: 17947728
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V, Ferraro G, Pergolizzi S, Sergi C, Laudani A, Settineri N, Alafaci E, Scimone A, Spano F, Spitaleri G.
    Oral Oncol; 2004 May 20; 40(5):525-31. PubMed ID: 15006626
    [Abstract] [Full Text] [Related]

  • 15. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R.
    Semin Oncol; 2004 Dec 20; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, Langmacher M, Baylor A, Lee M, Cullen KJ.
    Clin Cancer Res; 1999 Dec 20; 5(12):4097-104. PubMed ID: 10632346
    [Abstract] [Full Text] [Related]

  • 17. Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
    Chufal KS, Rastogi M, Srivastava M, Pant MC, Bhatt ML, Srivastava K.
    Jpn J Clin Oncol; 2006 Sep 20; 36(9):537-46. PubMed ID: 16905755
    [Abstract] [Full Text] [Related]

  • 18. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
    Le QT, Taira A, Budenz S, Jo Dorie M, Goffinet DR, Fee WE, Goode R, Bloch D, Koong A, Martin Brown J, Pinto HA.
    Cancer; 2006 May 01; 106(9):1940-9. PubMed ID: 16532436
    [Abstract] [Full Text] [Related]

  • 19. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G, Gruppo Oncologico Italia Meridionale.
    Lung Cancer; 2008 Sep 01; 61(3):369-77. PubMed ID: 18308419
    [Abstract] [Full Text] [Related]

  • 20. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
    Budach W, Hehr T, Budach V, Belka C, Dietz K.
    BMC Cancer; 2006 Jan 31; 6():28. PubMed ID: 16448551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.